This disclosure describes a
cannabinoid-based nanoplatform for treating
shingles, designed to enhance
bioavailability and
controlled release of active ingredients. The composition includes cannabinoids like
cannabidiol (CBD) and
cannabigerol (CBG), alongside flavonoids, polyphenols, and alkaloids, in oral and topical formulations. The oral
capsule combines cannabinoids with polyphenols and flavonoids to provide systemic anti-inflammatory, antiviral, and neuroprotective effects, particularly for nerve pain and
inflammation, including
postherpetic neuralgia. The
topical cream includes cannabinoids,
capsaicin, and
aloe vera, offering localized relief from pain,
itching, and
rash. The method targets both systemic and localized symptoms during the acute phase of
shingles, aiming to inhibit varicella-zoster
virus replication, disrupt viral
assembly, and prevent viral release, while also providing
immune modulation and anti-inflammatory benefits. The nanoplatform uses nano-emulsification techniques, producing particles smaller than 200 nm to ensure optimal delivery and therapeutic
efficacy, offering comprehensive relief for
shingles symptoms.